English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Autoimmune hepatitis (AIH) has been the subject of numerous studies, from the late 1940s when it first came to clinical attention, and various aspects of this disease have been analyzed throughout the world [1]. Although its clinical, laboratory and histological features, as well as demographical characteristics, have been extensively studied in many countries and in different ethnic groups, there have been no such statistics or analysis available for Iranian patients with AIH until now. The number of Iranian studies published so far about autoimmune hepatitis has been very limited. We only have two studies concerning the clinical characteristics of Iranian adult patients with AIH [2][3] and the information obtained can be summarized as follows: Iranian patients with AIH are typically women (male/female: 1:4), usually in their 30s and almost all of them have type 1 of the disease. We also have other Iranian studies regarding coeliac disease in patients with AIH [4][5], studies about cyclosporine therapy for AIH [6][7], surveys on the impact of immunosuppressive treatment on cirrhosis and liver fibrosis in AIH [8][9] and finally, some scattered studies related to the role of viruses and gene polymorphisms in AIH disease etiology [10][11][12][13]. However, there has not been any rigorous research conducted so far on the long-term outcomes of AIH in Iranian patients. In this issue of Hepatitis Monthly, Malekzadeh et al. analyzes both the clinical features and long term treatment outcomes of 102 Iranian patients diagnosed with AIH [14]. This article is both the first and the largest study detailing clinical aspects of AIH and long term outcomes based on data gathered from Iranian patients. According to the findings of this study, Iranian patients with AIH have several characteristics that are similar to other reported AIH series, these include; two age-peaks at presentation, clinical biochemical and histopathological features when AIH is first diagnosed, concurrent autoimmune diseases, and response rates to corticosteroids. We also now know that Iranian patients with AIH have an excellent 10-year survival rate of 96%, which is consistent with findings from previous studies carried out on other ethnic groups.

Autoimmune Hepatitis in Iran: What We Know, What We Don’t Know and Requirements for Better Management